The spelling of the word "DID CBER" may seem a bit odd to many, but it actually follows the phonetics of the English language. The first two letters "DI" are pronounced as /dɪ/, which is the short vowel sound of "i". The letter "D" that follows is pronounced as /d/, the consonant sound. The next three letters "CBE" are pronounced as /sbiː/. The final letter "R" is pronounced as /ɑr/, which sounds like the "ar" in "car". So, "DID CBER" is pronounced as /dɪdˈsbiːɑr/.
DID CBER is an abbreviation that stands for "Drug Information Database - Center for Biologics Evaluation and Research." It refers to a database maintained by the Center for Biologics Evaluation and Research (CBER), which is a division of the U.S. Food and Drug Administration (FDA).
The Drug Information Database is a comprehensive and authoritative source of information about various drugs and biologic products approved or regulated by CBER. It serves as a centralized repository of information for healthcare professionals, researchers, and the general public.
DID CBER contains a wide range of essential data about drugs and biologics, including their regulatory history, approved indications, labeling information, dosage forms, manufacturing information, and post-market safety surveillance reports. It offers details about the development, review, and approval processes conducted by CBER for these products.
This database plays a crucial role in facilitating access to accurate and up-to-date information, which aids in the safe and effective use of drugs and biologics. It serves as an invaluable resource for healthcare professionals who need to stay informed about new products, labeling updates, adverse events, and any other relevant information. Researchers can also benefit from the wealth of information present in this database for understanding the safety and efficacy profiles of drugs and biologics. Additionally, the general public can use it to access reliable information about the products they are prescribed or considering using.